CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 241,623	$ 93,459	$ 30,262
Cost of revenue:
Total cost of revenue	87,530	28,187	9,103
Gross profit	154,093	65,272	21,159
Operating expenses:
Research, development and clinical trials	36,055	26,812	22,304
Acquired in-process research and development expenses	27,212
Selling, general and administrative	119,553	69,897	38,283
Total operating expenses	182,820	96,709	60,587
Loss from operations	(28,727)	(31,437)	(39,428)
Other income (expense):
Interest expense	(10,791)	(3,726)	(3,874)
Other income (expense), net	12,847	(1,002)	(877)
Total other income (expense), net	2,056	(4,728)	(4,751)
Loss before income taxes	(26,671)	(36,165)	(44,179)
(Provision) benefit for income taxes	1,643	(66)	(36)
Net loss	$ (25,028)	$ (36,231)	$ (44,215)
Net loss per share attributable to common stockholders, basic	$ (0.77)	$ (1.23)	$ (1.6)
Net loss per share attributable to common stockholders, diluted	$ (0.77)	$ (1.23)	$ (1.6)
Weighted average common shares outstanding, basic	32,517,372	29,556,633	27,616,839
Weighted average common shares outstanding, diluted	32,517,372	29,556,633	27,616,839
Net product revenue [Member]
Revenue:
Total revenue	$ 176,069	$ 79,234	$ 29,657
Cost of revenue:
Total cost of revenue	41,015	16,970	9,031
Service Revenue [Member]
Revenue:
Total revenue	65,554	14,225	605
Cost of revenue:
Total cost of revenue	$ 46,515	$ 11,217	$ 72